EPISODE · Jan 8, 2026 · 37 MIN
The National Pharmaceutical Council President and CEO & Former Trump Drug Pricing Advisor, John O’Brien, PharmD, MPH
from Perspectives by the Leerink Center for Pharmacoeconomics · host The Leerink Center for Pharmacoeconomics
Melanie Whittington, PhD, Head of the Leerink Center for Pharmacoeconomics, talks with John M. O'Brien, PharmD, MPH, President and CEO of the National Pharmaceutical Council & Former Trump Drug Pricing Advisor, to tackle some big questions like if it is possible to reward innovation without busting budgets and how to get to a sustainable, innovation-friendly, patient-centered drug pricing system. Additional resources: Subscribe to NPC’s Newsletter https://www.npcnow.org/subscribe-updates IRA Impact on Pharmaceutical Investment: Insights From Investor Interviews (Health Affairs Scholar) https://academic.oup.com/healthaffairsscholar/article/3/9/qxaf156/8223954 How Time Is Accounted For When Modeling Pharmaceutical Impacts: Investment vs Assessment Perspectives (Health Affairs Scholar) https://academic.oup.com/healthaffairsscholar/article/3/9/qxaf169/8244606 The IRA and Drug Development: Potential Early Signals of Impact on Post-Approval Clinical Trials (Therapeutic Innovation & Regulatory Science) https://link.springer.com/article/10.1007/s43441-025-00774-2 Subsequent Indications in Oncology Drugs: Pathways, Timelines, and the Inflation Reduction Act (Therapeutic Innovation & Regulatory Science) https://link.springer.com/article/10.1007/s43441-024-00706-6 Unintended Consequences of the Inflation Reduction Act: Clinical Development Toward Subsequent Indications (American Journal of Managed Care) https://www.ajmc.com/view/unintended-consequences-of-the-inflation-reduction-act-clinical-development-toward-subsequent-indications The Impact of the Inflation Reduction Act’s Drug Price Negotiation Program on Incentives for Clinical Development of New Drugs (Value in Health) https://www.valueinhealthjournal.com/article/S1098-3015(25)02527-6/fulltext?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301525025276%3Fshowall%3Dtrue Follow John O’Brien on LinkedIn https://www.linkedin.com/in/drjmob/
Embed this episode
Ready to play
The National Pharmaceutical Council President and CEO & Former Trump Drug Pricing Advisor, John O’Brien, PharmD, MPH
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.